ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10

Published: 29 May 2024

  • Views:

    Views Icon 123
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).

This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary outcome measures were change in body weight (from randomisation to week 52) and change in normoglycaemia.

Semaglutide showed superior reduction in body weight and reversion to normal glycaemia compared to placebo, as well as improvements in other cardiometabolic risk factors.

1. What is the background of the STEP 10 trial?
2. What was the study design and baseline characteristics of the randomised patients?
3. What findings did you present at ECO 24?
4. What are the take home messages for practice?
5. What are the next steps?
6. What are some of the challenges with anti-obesity drugs?

Support: This is an independent content produced by Radcliffe Cardiology.

Videographer: Oliver Miles
Interviewer: Mirjam Boros


You must be to comment. If you are not registered, you can register here.